This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

22 Biopharma Stocks With Breakout Potential in 2012

Stock quotes in this article: ELN, GERN, ACAD, BIIB, ARQL, FOLD, CELG, ZIOP, VICL, LXRX, ZLCS, PFE, LLY, EXAS, NKTR

Exact Sciences (EXAS)
Diagnostic/indication: Cologuard to detect colon cancer and pre-cancerous polyps in the colon. (phase III trial)
Top-line results expected in the fourth quarter.
Cologuard is a non-invasive test designed to measure genetic abnormalities in stool that detects early-stage colon cancer and pre-cancerous polyps. Currently available colon cancer screening test can't reliably detect cancer at early stages, which means patients at risk must undergo expensive and invasive colonoscopies. Cologuard won't replace colonoscopies but could cut down on the number of the invasive tests performed.
The phase III "Deep-C" study is designed to prospectively validate the sensitivity and specificity of Cologuard compared to colonoscopy. If positive, Exact Sciences will seek FDA approval in the first quarter of next year.


Geron (GERN)
Drug/indication: Imetelstat in non-small cell lung cancer (phase II trial)
Top-line results expected in the fourth quarter

Geron (GERN) took a beating late last year when it gave up on its embryonic stem cell therapy. Now, the company is focusing its drug development activities on its cancer therapeutics, many of which pre-date its stem-cell research. Geron will help its turnaround efforts a great deal if it can manage to produce a win from a phase II lung cancer study of imetelstat.
The study compares imetelstat to standard of care as maintenance therapy in non-small cell lung cancer patients who responded to previous chemotherapy. The primary endpoint is improvement in progression-free survival.


Lexicon Pharmaceuticals (LXRX)
Drug/indication: LX4211 in Type 2 diabetes (phase II trial)
Top line results expected by the end of the second quarter
The phase II study compares LX4211 plus metformin to metformin alone in type 2 diabetes patients with inadequate blood sugar control. The study's primary endpoint will measure the change in HbA1c, or blood glucose levels from baseline to week 12.


Nektar Therapeutics (NKTR)
Drug/indication: NKTR-118 for opioid-induced constipation (phase III trials)
Top-line results expected in the fourth quarter
Nektar's partner Astrazeneca (AZN) is conducting the "KODIAC" trials, consisting of two phase III placebo-controlled efficacy and an open-label, placebo-controlled long-term safety study. The studies are designed to determine the efficacy and safety of NKTR-118, a once-daily tablet, for the treatment of constipation in patients taking prescription opioid medications.


Vical (VICL)
Drug/indication: Allovectin in melanoma (phase III trial)
Top-line results expected in the fourth quarter
The phase III study compares Allovectin (injected directly into melanoma lesions) to dacarbazine or temozolomide in patients with recurrent metastatic melanoma. The primary endpoint of the study is durable response rate at 24 weeks but the more important and necessary (for approval) secondary endpoint is overall survival.


4 of 5

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,804.71 -238.19 -1.40%
S&P 500 1,946.16 -26.13 -1.32%
NASDAQ 4,422.0850 -71.3050 -1.59%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs